DKD is an often fatal long-term complication of type 2 diabetes which is the most common cause of severe renal disease. It affects one third of people with type 2 diabetes and has no viable treatment until now.
Category: CSL Limited
SK Chemicals’ hemophilia drug approved in Canada
SK Chemicals, the biopharmaceuticals unit of South Korea’s SK Group, has obtained regulatory approval to sell its hemophilia treatment in Canada, marking another step forward in breaking into overseas markets. SK Chemicals said Sunday that Health Canada, the country’s drug regulator, has granted marketing and sales approval for Afstyla, a biologic drug for hemophilia developed by SK Chemicals and licensed out to Australian biotech firm CSL Ltd. in 2009.